Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.72 [0.59, 0.87] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | crucial | - |
deaths (OS) (extension) | 0.69 [0.57, 0.84] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.76 [0.63, 0.92] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | important | - |
DCR | 1.15 [0.79, 1.68] | | > 1 | | 0% | 1 study (1/-) | 76.8 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 1.56 [0.91, 2.65] | | > 1 | | 0% | 1 study (1/-) | 94.8 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 5.17 [1.48, 18.09] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 3.39 [2.34, 4.94] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 5.64 [3.80, 8.35] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 11.25 [6.30, 20.10] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Colitis TRAE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 21.14 [1.23, 363.94] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 8.25 [0.43, 156.83] | | < 1 | | 0% | 1 study (1/-) | 8.3 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 52.70 [7.19, 385.99] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 32.40 [7.79, 134.72] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 6.16 [0.31, 123.62] | | < 1 | | 0% | 1 study (1/-) | 12.0 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 0.43 [0.11, 1.68] | | < 1 | | 0% | 1 study (1/-) | 88.8 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.17 [0.02, 1.39] | | < 1 | | 0% | 1 study (1/-) | 95.0 % | NA | not evaluable | | non important | - |
Chills AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 2.04 [0.07, 60.99] | | < 1 | | 0% | 1 study (1/-) | 34.3 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.76 [0.17, 3.43] | | < 1 | | 0% | 1 study (1/-) | 63.9 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 21.14 [1.23, 363.94] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 16.77 [0.96, 293.61] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 2.44 [1.21, 4.94] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 4.12 [0.46, 37.08] | | < 1 | | 0% | 1 study (1/-) | 10.5 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 18.42 [5.64, 60.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 34.83 [8.39, 144.67] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 1.36 [0.30, 6.14] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 6.16 [0.31, 123.62] | | < 1 | | 0% | 1 study (1/-) | 12.0 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 2.07 [0.61, 6.95] | | < 1 | | 0% | 1 study (1/-) | 12.1 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 1.02 [0.06, 16.34] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |